Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation
- PMID: 34039488
- DOI: 10.1016/j.jhep.2021.01.007
Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation
Abstract
Liver transplantation represents a life-saving treatment for patients with decompensated cirrhosis, a severe condition associated with a high risk of waiting list mortality. When decompensation occurs rapidly in the presence of extrahepatic organ failures, the condition is called acute-on-chronic liver failure, which is associated with an even higher risk of death, though liver transplantation can also markedly improve survival in affected patients. However, there are still gaps in our understanding of how to optimise prioritisation and organ allocation, as well as survival among patients with acute-on-chronic liver failure (both before and after transplant). Moreover, it is urgent to address inequalities in access to liver transplantation in patients with severe alcoholic hepatitis and non-alcoholic steatohepatitis. Several controversies still exist regarding gender and regional disparities, as well as the use of suboptimal donor grafts. In this review, we aim to provide a critical perspective on the role of liver transplantation in patients with decompensated cirrhosis and address areas of ongoing uncertainty.
Keywords: Acute-on-chronic liver failure; Alcohol-associated acute hepatitis; Allocation models; Futility; Liver transplantation; Non-alcoholic steatohepatitis; Waiting list.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest PB declares no conflict of interest with any financial organization regarding the manuscript, however she received fees from Biotest, Germany, Kedrion, Italy and Chiesi Farmaceutici, Italy. DS declares no conflict of interest with any financial organization regarding the manuscript, however he received fees from Biotest, Germany and Goliver Therapeutics, France. CD declares no conflict of interest with any commercial organization regarding the manuscript, however he received fees from Biotest, Germany. NT has institutional grant support from Gilead Sciences, USA and Genentech/Roche, USA. RJ has research collaborations with Yaqrit Limited, UK and Takeda, Japan. He is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma, UK. He is also the founder of Yaqrit Limited, a spin out company from University College London. VS, HP declare no conflict of interest with any commercial organization. Please refer to the accompanying ICMJE disclosure forms for further details.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical